Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

NCT05921253 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT05921253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05921253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)
Lead sponsor
University of Oklahoma
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2023
Completion date
September 30, 2027
Enrollment
104 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, lymphoma